Vertex Pharma To Acquire ViaCyte For $320 Mln In Cash

RTTNews | 998 days ago
Vertex Pharma To Acquire ViaCyte For $320 Mln In Cash

(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) announced Monday that the company has entered into a definitive agreement under which Vertex will acquire privately-held biotechnology company ViaCyte for $320 million in cash.

ViaCyte is focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes (T1D). The acquisition of ViaCyte provides Vertex with complementary assets, capabilities and technologies including additional human stem cell lines, intellectual property around stem cell differentiation, and Good Manufacturing Practice (GMP) manufacturing facilities for cell-based therapies that could accelerate Vertex's ongoing T1D programs.

The acquisition also provides access to novel hypoimmune stem cell assets via the ViaCyte collaboration with CRISPR Therapeutics.

Vertex anticipates the acquisition will close later this year, subject to certain customary conditions being met.

read more
Vertex Receives CHMP Positive Opinion For The First CRISPR/Cas9 Gene-Edited Therapy CASGEVY

Vertex Receives CHMP Positive Opinion For The First CRISPR/Cas9 Gene-Edited Therapy CASGEVY

Vertex Pharmaceuticals Inc. (VRTX) announced Friday that the European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the conditional approval of CASGEVY (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy, for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).
RTTNews | 476 days ago
Vertex Pharma Inks Licensing Agreement To Use CRISPR Therapeutics' Gene Editing Technology

Vertex Pharma Inks Licensing Agreement To Use CRISPR Therapeutics' Gene Editing Technology

Biotechnology company Vertex Pharmaceuticals, Inc. (VRTX) and gene editing company CRISPR Therapeutics, Inc. (CRSP) announced Monday that they have entered into a new non-exclusive licensing agreement for the use of CRISPR Therapeutics' gene editing technology, known as CRISPR/Cas9, to accelerate the development of Vertex's hypoimmune cell therapies for type 1 diabetes (T1D).
RTTNews | 739 days ago
Vertex Pharma Says FDA Lifts Clinical Hold On Phase 1/2 Trial Of VX-880 To Treat Type 1 Diabetes

Vertex Pharma Says FDA Lifts Clinical Hold On Phase 1/2 Trial Of VX-880 To Treat Type 1 Diabetes

Vertex Pharmaceuticals Inc. (VRTX) announced Tuesday that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemia.
RTTNews | 1004 days ago
Pound Falls As European Shares Extend Losses On Growth Worries

Pound Falls As European Shares Extend Losses On Growth Worries

The British pound weakened against other major currencies in the European session on Friday, as European shares traded lower, extending steep losses from the previous session after U.S. President Donald Trump announced significantly harsher-than-expected tariffs.
RTTNews | 4h 27min ago
DAX Down 2.2% As Stocks Extend Recent Plunge

DAX Down 2.2% As Stocks Extend Recent Plunge

After suffering its worst setback in about eight months on Thursday, the German market is deep down in negative territory again with stocks reeling under a fresh bout of selling pressure on Friday amid concerns about growth following U.S. President Donald Trump's tariff moves.
RTTNews | 4h 31min ago
Pound Falls Against Majors

Pound Falls Against Majors

The British pound weakened against other major currencies in the European session on Friday.
RTTNews | 5h 9min ago
European Shares Extend Losses On Growth Worries

European Shares Extend Losses On Growth Worries

European shares traded lower on Friday, extending steep losses from the previous session after U.S. President Donald Trump announced significantly harsher-than-expected tariffs.
RTTNews | 5h 13min ago